318 related articles for article (PubMed ID: 32243578)
21. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
El-Ghazzi N; Lavaud P
Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
[No Abstract] [Full Text] [Related]
22. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
Sadaat M; Jang S
J Immunother Cancer; 2018 Jun; 6(1):49. PubMed ID: 29871698
[TBL] [Abstract][Full Text] [Related]
23. Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors: Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis.
Grewal US; Thotamgari SR; Shah PR; Uppal JK; Gaddam SJ
Eur J Cancer; 2021 Aug; 153():270-271. PubMed ID: 34148729
[No Abstract] [Full Text] [Related]
24. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
Abdelhafeez AAM; Shohdy KS; Ibrahim W
Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
Mineiro Dos Santos Garrett NF; Carvalho da Costa AC; Barros Ferreira E; Damiani G; Diniz Dos Reis PE; Inocêncio Vasques C
PLoS One; 2021; 16(8):e0255716. PubMed ID: 34358260
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab].
Uhara H; Itakura E
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1017-1026. PubMed ID: 31273168
[TBL] [Abstract][Full Text] [Related]
27. Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma.
Scovell JM; Benz K; Samarska I; Kohn TP; Hooper JE; Matoso A; Herati AS
JAMA Oncol; 2020 Aug; 6(8):1297-1299. PubMed ID: 32556068
[TBL] [Abstract][Full Text] [Related]
28. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab plus ipilimumab in non-small-cell lung cancer.
Reck M; Borghaei H; O'Byrne KJ
Future Oncol; 2019 Jul; 15(19):2287-2302. PubMed ID: 31066582
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review.
Geusens D; Dierickx D; Carton S; Van Cutsem E; Dekervel J
Clin Colorectal Cancer; 2024 Jun; 23(2):194-197. PubMed ID: 38519390
[No Abstract] [Full Text] [Related]
31. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.
Kuriyama H; Fukushima S; Nakahara S; Kanemaru H; Miyashita A; Aoi J; Tomita Y; Kawasaki T; Nosaka K; Ihn H
J Dermatol; 2020 Jun; 47(6):e235-e237. PubMed ID: 32275077
[No Abstract] [Full Text] [Related]
32. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
33. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.
Uehara J; Yoshino K; Sugiyama E; Ohkuma K; Oaku S; Yamashita C; Hiura A; Fujisawa Y
J Dermatol; 2020 Jun; 47(6):e237-e239. PubMed ID: 32270507
[No Abstract] [Full Text] [Related]
34. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
Noseda R; Bertoli R; Müller L; Ceschi A
J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
[TBL] [Abstract][Full Text] [Related]
35. Thyroid atrophy and pancreatic involution after cancer Immunotherapy.
Haupt F; Prosch H; Ebner L
Rofo; 2020 Jul; 192(7):688-690. PubMed ID: 32193884
[No Abstract] [Full Text] [Related]
36. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
Cohen R; Pellat A; Boussion H; Svrcek M; Lopez-Trabada D; Trouilloud I; Afchain P; André T
Bull Cancer; 2019 Feb; 106(2):137-142. PubMed ID: 30327191
[TBL] [Abstract][Full Text] [Related]
37. Immune-checkpoint inhibitors in pituitary malignancies.
Di Nunno V; Franceschi E; Tosoni A; Gatto L; Maggio I; Lodi R; Bartolini S; Brandes AA
Anticancer Drugs; 2022 Jan; 33(1):e28-e35. PubMed ID: 34348358
[TBL] [Abstract][Full Text] [Related]
38. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases.
Xu Z; Li H; Yu X; Luo J; Zhang Z
Hematology; 2024 Dec; 29(1):2340144. PubMed ID: 38606818
[TBL] [Abstract][Full Text] [Related]
39. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab.
Satzger I; Ivanyi P; Länger F; Kreipe HH; Schaper-Gerhardt K; Beutel G; Cornberg M; Gutzmer R
Eur J Cancer; 2018 Apr; 93():150-153. PubMed ID: 29472154
[No Abstract] [Full Text] [Related]
40. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]